Figure 1
Figure 1. Baseline NF-κB expression in WM cells. (A) NF-κBp65 DNA binding activity was assessed in vitro using nuclear extracts using the Active Motif assay. We compared BM isolated CD19+ cells from 4 patients with WM to one healthy donor. Jurkat nuclear extracts provided as a positive control in the kit were used as a control in the first 3 conditions. P indicates patient; NBM, healthy donor normal BM. WT and Mut are wild-type and mutated consensus competitor oligonucleotides, respectively. Data represent mean plus or minus SD of triplicate experiments. (B) Immunofluor-escence for phospho-NF-κBp65 on BM isolated CD19+ cells from one patient with WM compared with one healthy donor (NBM). Immunocytochemical analysis was assessed using anti–p-NF-κBp65 antibody (ii). DAPI was used to stain nuclei (i). (iii) The merge of i and ii panels.

Baseline NF-κB expression in WM cells. (A) NF-κBp65 DNA binding activity was assessed in vitro using nuclear extracts using the Active Motif assay. We compared BM isolated CD19+ cells from 4 patients with WM to one healthy donor. Jurkat nuclear extracts provided as a positive control in the kit were used as a control in the first 3 conditions. P indicates patient; NBM, healthy donor normal BM. WT and Mut are wild-type and mutated consensus competitor oligonucleotides, respectively. Data represent mean plus or minus SD of triplicate experiments. (B) Immunofluor-escence for phospho-NF-κBp65 on BM isolated CD19+ cells from one patient with WM compared with one healthy donor (NBM). Immunocytochemical analysis was assessed using anti–p-NF-κBp65 antibody (ii). DAPI was used to stain nuclei (i). (iii) The merge of i and ii panels.

Close Modal

or Create an Account

Close Modal
Close Modal